Perinatal HIV-1 transmission -: Interaction between zidovudine prophylaxis and mode of delivery in the French Perinatal Cohort

被引:201
|
作者
Mandelbrot, L
Le Chenadec, J
Berrebi, A
Bongain, M
Bénifla, JL
Delfraissy, JF
Blanche, S
Mayaux, MJ
机构
[1] Hop Cochin Port Royal, Serv Gynecol Obstet 1, F-75014 Paris, France
[2] INSERM, U149, Paris, France
[3] INSERM, U292, Le Kremlin Bicetre, France
[4] Hop La Grave, Serv Gynecol Obstet, Toulouse, France
[5] Hop Archet 2, Serv Gynecol Obstet, Nice, France
[6] Hop Bichat Claude Bernard, Serv Gynecol Obstet, F-75877 Paris, France
[7] Hop Kremlin Bicetre, Serv Med Interne, Le Kremlin Bicetre, France
[8] Hop Necker Enfants Malad, Serv Pediat, Paris, France
来源
关键词
D O I
10.1001/jama.280.1.55
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context.-It is unclear whether elective cesarean delivery may have a protective effect against the transmission of human immunodeficiency virus 1 (HIV-1). Objective.-To investigate whether mode of delivery has an impact on perinatal HIV-1 transmission in the presence of zidovudine prophylaxis. Design.-A prospective cohort study. Setting.-The 85 perinatal centers in the French Perinatal Cohort, from 1985 to 1996. Patients.-A total of 2834 singleton children born to mothers with HIV-1 infection. Main Outcome Measure.-Human immunodeficiency virus 1 infection of the infant. Results.-No zidovudine was used in 1917 pregnancies and zidovudine prophylaxis was used in 902 pregnancies. Cesarean deliveries were performed in 10.9% on an emergent basis and in 8.3% electively, prior to labor or membrane rupture. In 1917 mothers who did not receive zidovudine, of 1877 with information on mode of delivery, 17.2% transmitted HIV-1 to their child. Risk factors statistically significantly associated with transmission were maternal p24 antigenemia, cervicovaginal infections during pregnancy, amniotic fluid color, and rupture of membranes 4 hours or more before delivery. Mode of delivery was not related to transmission. in 902 mothers receiving zidovudine, transmission was 6.4% in 872 with information on mode of delivery, and elective cesarean delivery (n = 133) was associated with a lower transmission rate than emergent cesarean or vaginal delivery (0.8%, 11.4%, and 6.6%, respectively; P=.002). In a multivariate analysis of all mother-child pairs, including obstetrical risk factors, maternal p24 antigenemia, and zidovudine prophylaxis, interaction between mode of delivery and zidovudine prophylaxis was significant (P=.007). In the multivariate analysis of pregnancies with zidovudine prophylaxis, factors related to transmission rate were maternal p24 antigenemia, amniotic fluid color, and mode of delivery. Adjusted odds ratios (95% confidence intervals) were 1.6 (0.7-3.6) for emergent cesarean delivery and 0.2 (0.0-0.9) for elective cesarean delivery (P =.04) in comparison with vaginal delivery. Conclusions.-We observed an interaction between zidovudine prophylaxis and elective cesarean delivery in decreasing transmission of HIV-1 from mother to child. This observation may have clinical implications for prevention.
引用
收藏
页码:55 / 60
页数:6
相关论文
共 50 条
  • [21] Perinatal HIV-1 transmission discussed in Geneva
    Bradbury, J
    McCarthy, M
    [J]. LANCET, 1998, 352 (9121): : 39 - 39
  • [22] A COST-ANALYSIS OF PERINATAL ZIDOVUDINE (AZT) PROPHYLAXIS TO REDUCE VERTICAL HIV TRANSMISSION
    OHNING, BL
    JOHNSON, GM
    [J]. PEDIATRIC RESEARCH, 1995, 37 (04) : A297 - A297
  • [23] Independent effects of nevirapine prophylaxis and HIV-1 RNA suppression in breast milk on early perinatal HIV-1 transmission
    Chung, Michael H.
    Kiarie, James N.
    Richardson, Barbra A.
    Lehman, Dara A.
    Overbaugh, Julie
    Njiri, Francis
    John-Stewart, Grace C.
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2007, 46 (04) : 472 - 478
  • [24] Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial
    Shaffer, N
    Chuachoowong, R
    Mock, PA
    Bhadrakom, C
    Siriwasin, W
    Young, NL
    Chotpitayasunondh, T
    Chearskul, S
    Roongpisuthipong, A
    Chinayon, P
    Karon, J
    Mastro, TD
    Simonds, RJ
    [J]. LANCET, 1999, 353 (9155): : 773 - 780
  • [25] Zidovudine resistance phenotype and risk of perinatal HIV-1 transmission in zidovudine monotherapy-treated mothers with moderately advanced disease
    Bauer, GR
    Welles, SL
    Colgrove, RR
    Pitt, J
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2003, 34 (03) : 312 - 319
  • [26] HIV-1 INFECTIONS IN PREGNANCY AND PERINATAL TRANSMISSION OF HIV-1 - CURRENT ISSUES
    SISON, AV
    SEVER, JL
    [J]. PEDIATRIC AIDS AND HIV INFECTION-FETUS TO ADOLESCENT, 1992, 3 (01): : 5 - 11
  • [27] Maternal immune response to HIV-1 and perinatal transmission
    Landay, AL
    Siegel, JN
    Rich, K
    [J]. IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA, 1998, 18 (02) : 355 - +
  • [28] Perinatal HIV infection and the effect of zidovudine therapy on transmission in rural and urban counties - Zidovudine use to reduce perinatal HIV type-1 transmission in an urban medical center
    MacDonald, MG
    [J]. PEDIATRIC AIDS AND HIV INFECTION-FETUS TO ADOLESCENT, 1996, 7 (06): : 434 - 435
  • [29] Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus
    Wade, NA
    Birkhead, GS
    Warren, BL
    Charbonneau, TT
    French, PT
    Wang, L
    Baum, JB
    Tesoriero, JM
    Savicki, R
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (20): : 1409 - 1414
  • [30] Preventing perinatal HIV transmission: Zidovudine use during pregnancy
    Carmichael, C
    [J]. AMERICAN FAMILY PHYSICIAN, 1997, 55 (01) : 171 - 174